RS50102B - Farmaceutske smeše koje sadrže plazma protein - Google Patents

Farmaceutske smeše koje sadrže plazma protein

Info

Publication number
RS50102B
RS50102B YUP-166/00A YU16600A RS50102B RS 50102 B RS50102 B RS 50102B YU 16600 A YU16600 A YU 16600A RS 50102 B RS50102 B RS 50102B
Authority
RS
Serbia
Prior art keywords
plasma protein
organic solvent
pharmaceutical composition
water
composition containing
Prior art date
Application number
YUP-166/00A
Other languages
English (en)
Inventor
Lajos Hegedus
Krisztina Krempels
Krisztina Paal
Gabor Petho
Original Assignee
Teva Pharmaceutical Works Plc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Works Plc., filed Critical Teva Pharmaceutical Works Plc.,
Publication of YU16600A publication Critical patent/YU16600A/sh
Publication of RS50102B publication Critical patent/RS50102B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

U vodi rastvoran produkt bez organskog rastvarača ili farmaceutska formulacija u čvrstom ili tečnom obliku i njihovi pravi vodeni rastvori bez organskog rastvarača uglavnom za parenteralnu primenu, naznačeni time, što sadrže: (A) terapeutski aktivno jedinjenje koje ima malu rastvorljivost u vodi (<1 "l0-4 mol/1) i znatan afmitetet vezivanja za plazma proteine (aktivnu supstancu), i (B) plazma proteinsku frakciju u kontrolisanom stanju agregacije, pri čemu su aktivna supstanca (A) i plažma proteinska frakcija (B) nekovalentno vezane jedna za drugu i što opciono dalje sadrži (C) farmaceutski prihvatljive i uglavnom parenteralno prihvatljive aditive za formulaciju - kao što su voda, stabilizatori i kontrolori agregacije proteina. Prijava sadrži još 35 patentnih zahteva.
YUP-166/00A 1997-09-18 1998-09-17 Farmaceutske smeše koje sadrže plazma protein RS50102B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9701554A HUP9701554D0 (en) 1997-09-18 1997-09-18 Pharmaceutical composition containing plazma proteins

Publications (2)

Publication Number Publication Date
YU16600A YU16600A (sh) 2003-08-29
RS50102B true RS50102B (sr) 2009-01-22

Family

ID=90014222

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-166/00A RS50102B (sr) 1997-09-18 1998-09-17 Farmaceutske smeše koje sadrže plazma protein

Country Status (33)

Country Link
US (5) US6743826B1 (sr)
EP (1) EP0981375B1 (sr)
JP (1) JP2001508806A (sr)
KR (1) KR100587962B1 (sr)
CN (1) CN1189216C (sr)
AR (1) AR017120A1 (sr)
AT (1) ATE230611T1 (sr)
AU (1) AU734695B2 (sr)
BG (1) BG64749B1 (sr)
BR (1) BR9812469A (sr)
CA (1) CA2269923C (sr)
CZ (1) CZ301326B6 (sr)
DE (1) DE69810612T2 (sr)
DK (1) DK0981375T3 (sr)
EA (1) EA004700B1 (sr)
ES (1) ES2187062T3 (sr)
HR (1) HRP980499A2 (sr)
HU (1) HUP9701554D0 (sr)
IL (1) IL135055A (sr)
LT (1) LT4736B (sr)
LV (1) LV12493B (sr)
NO (1) NO325294B1 (sr)
NZ (1) NZ503302A (sr)
PL (1) PL193067B1 (sr)
PT (1) PT981375E (sr)
RO (1) RO118695B1 (sr)
RS (1) RS50102B (sr)
SI (1) SI20189B (sr)
SK (1) SK284683B6 (sr)
TR (1) TR200001545T2 (sr)
TW (1) TWI222365B (sr)
WO (1) WO1999013914A1 (sr)
ZA (1) ZA988585B (sr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) * 1999-02-11 2000-08-17 Kinetana Inc. Serum albumin-based parenteral formulations of polyene macrolides
MXPA02002439A (es) 1999-09-16 2002-07-30 Novo Nordisk As Composicion para fertilizacion in vitro.
AU2001253336A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
BR0110150A (pt) * 2000-04-10 2004-04-27 Teva Pharma Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose
US20020192280A1 (en) * 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EA200500210A1 (ru) 2002-07-16 2005-06-30 Медексис С. А. Конъюгаты стероидов, их получение и их применение
GR1004274B (el) 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US8391959B2 (en) * 2004-09-29 2013-03-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Composition for improving efficiency of drug delivery
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
PT2079456E (pt) 2007-04-04 2013-03-13 Sigmoid Pharma Ltd Composições farmacêuticas de ciclosporina
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2009116557A1 (ja) * 2008-03-21 2009-09-24 富士フイルム株式会社 薬剤含有組成物
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
BRPI1012196B1 (pt) 2009-05-18 2021-11-30 Sublimity Therapeutics Limited Composição compreendendo gotas de óleo
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038068A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
CN102802617B (zh) * 2009-12-18 2016-05-11 埃克索多斯生命科学有限合伙公司 用于稳定的液体药物制剂的方法和组合物
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2942867C (en) 2014-03-18 2022-08-30 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
CN107106644B (zh) 2014-11-07 2022-04-15 卓越治疗有限公司 包含环孢菌素的组合物
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
WO2016182929A1 (en) 2015-05-08 2016-11-17 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
WO2016187147A1 (en) * 2015-05-15 2016-11-24 Fl Therapeutics Llc Docetaxel and human serum albumin complexes
CN107920991A (zh) * 2015-06-18 2018-04-17 马丁尼斯生物制药纳米技术公司 治疗炎性疾病或病状的组合物和方法
US20170128480A1 (en) * 2015-11-09 2017-05-11 Max A. Cayo Cardiac Glycosides for the Treatment of Hypercholesterolemia
CN109789154B (zh) * 2016-08-03 2021-05-14 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂
CN115487312A (zh) 2016-10-27 2022-12-20 珠海贝海生物技术有限公司 多西他赛和人血清白蛋白的中性pH组合物
JP7134995B2 (ja) 2017-03-20 2022-09-12 スペクトラル プラットフォームス インコーポレイテッド 微生物を検出し特徴づけるための分光法
BR112020000196A2 (pt) 2017-07-07 2020-07-07 Epicentrx, Inc. composições para administração parenteral de agentes terapêuticos
PL3761960T3 (pl) 2018-03-09 2024-04-15 Kiora Pharmaceuticals Gmbh Preparat okulistyczny
EP3811982A1 (en) * 2019-10-25 2021-04-28 Université de Strasbourg Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
CN111529506B (zh) * 2020-05-18 2021-09-03 同济大学 一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN115236216B (zh) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833013A (sr) * 1971-08-30 1973-05-07
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5356927A (en) * 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr) 1996-09-27 1997-09-21 Tureks Turunc Madencilik Ic Ve Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
NO325294B1 (no) 2008-03-17
EP0981375A1 (en) 2000-03-01
BG104245A (en) 2000-11-30
NO20001371L (no) 2000-05-18
LV12493B (en) 2001-01-20
DE69810612D1 (de) 2003-02-13
CN1189216C (zh) 2005-02-16
CN1270529A (zh) 2000-10-18
PL193067B1 (pl) 2007-01-31
PT981375E (pt) 2003-04-30
EP0981375B1 (en) 2003-01-08
ATE230611T1 (de) 2003-01-15
DE69810612T2 (de) 2003-10-02
US20100076008A1 (en) 2010-03-25
TR200001545T2 (tr) 2000-10-23
BG64749B1 (bg) 2006-02-28
US7501455B2 (en) 2009-03-10
ZA988585B (en) 2000-03-13
ES2187062T3 (es) 2003-05-16
BR9812469A (pt) 2002-02-05
RO118695B1 (ro) 2003-09-30
KR20010052072A (ko) 2001-06-25
US20050064028A1 (en) 2005-03-24
AU9362398A (en) 1999-04-05
CA2269923C (en) 2003-07-22
LT4736B (lt) 2000-12-27
EA200000331A1 (ru) 2000-10-30
TWI222365B (en) 2004-10-21
IL135055A (en) 2004-09-27
CA2269923A1 (en) 1999-03-25
US8946167B2 (en) 2015-02-03
SI20189A (sl) 2000-10-31
HUP9701554D0 (en) 1997-11-28
LV12493A (en) 2000-06-20
EA004700B1 (ru) 2004-06-24
WO1999013914A1 (en) 1999-03-25
LT2000018A (en) 2000-08-25
PL339369A1 (en) 2000-12-18
JP2001508806A (ja) 2001-07-03
NZ503302A (en) 2001-08-31
IL135055A0 (en) 2001-05-20
SI20189B (sl) 2007-10-31
US6743826B1 (en) 2004-06-01
DK0981375T3 (da) 2003-05-05
NO20001371D0 (no) 2000-03-16
SK284683B6 (sk) 2005-09-08
HRP980499A2 (en) 1999-12-31
US7119124B2 (en) 2006-10-10
US20040014655A1 (en) 2004-01-22
KR100587962B1 (ko) 2006-06-13
CZ301326B6 (cs) 2010-01-20
AR017120A1 (es) 2001-08-22
CZ2000952A3 (cs) 2000-09-13
US20070232536A1 (en) 2007-10-04
SK3292000A3 (en) 2000-08-14
AU734695B2 (en) 2001-06-21
YU16600A (sh) 2003-08-29

Similar Documents

Publication Publication Date Title
RS50102B (sr) Farmaceutske smeše koje sadrže plazma protein
Renau et al. Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa
WO2005028516A3 (en) Albumin-binding derivatives of therapeutic peptides
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
RS52706B (sr) Formiranje osušene rekonstituisane vezikule za farmaceutsku primenu
HRP990272B1 (en) Water-soluble pharmaceutical composition in an ionic complex and the use thereof
MX9709094A (es) Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina.
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
HRP20020880B1 (en) New pharmaceutical composition
DK0580817T3 (da) Farmaceutisk præparat og fremgangsmåde til fremstilling deraf
MA26490A1 (fr) Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
ZA932538B (en) Topical Composition
ATE226451T1 (de) Verfahren zum lösen von pharmazeutischen wirkstoffen in wasser und in wässrige träger
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ATE422356T1 (de) Pharmazeutische zubereitungen
ITMI921831A1 (it) Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
JPH03169807A (ja) 脂肪親和性薬剤の注射用組成物
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
DE69602886T2 (de) Im kardiovaskulären System aktive seco-D-Steroide und diese enthaltende pharmazeutische Zubereitungen
ES2079687T3 (es) Composicion topica.
GEP20053581B (en) Pharmaceutical Composition and Method for Preparation Thereof